Cargando…

Selective inhibition of low-affinity memory CD8(+) T cells by corticosteroids

Patients treated with immune checkpoint blockade (ICB) sometimes experience immune-related adverse events (irAEs), requiring immuno-suppressive drugs such as corticosteroids despite the possibility that immunosuppression may impair the antitumor effects of ICB. Here, we address the dilemma of using...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tokunaga, Akihiro, Sugiyama, Daisuke, Maeda, Yuka, Warner, Allison Betof, Panageas, Katherine S., Ito, Sachiko, Togashi, Yosuke, Sakai, Chika, Wolchok, Jedd D., Nishikawa, Hiroyoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Rockefeller University Press 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888983/ https://www.ncbi.nlm.nih.gov/pubmed/31537643 http://dx.doi.org/10.1084/jem.20190738

Ejemplares similares

The future of cancer immunotherapy: microenvironment-targeting combinations
por: Murciano-Goroff, Yonina R., et al.
Publicado: (2020)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Efficacy of immunotherapy for melanoma brain metastases in patients with concurrent corticosteroid exposure
por: Tringale, Kathryn R, et al.
Publicado: (2023)

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
por: Rosner, Samuel, et al.
Publicado: (2018)

The cancer epigenome: Non‐cell autonomous player in tumor immunity
por: Kato, Shinichiro, et al.
Publicado: (2022)

Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment()
por: Cassidy, Michael R., et al.
Publicado: (2017)

Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience
por: Page, David B, et al.
Publicado: (2014)

Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy
por: Atkinson, Thomas M, et al.
Publicado: (2023)

Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness
por: Hirschhorn, Daniel, et al.
Publicado: (2021)

Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab
por: Yuan, Jianda, et al.
Publicado: (2013)

Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer
por: Inamori, Koji, et al.
Publicado: (2021)

Refusing to TAP out: 16 new human TEIPPs identified
por: Gigoux, Mathieu, et al.
Publicado: (2018)

An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity
por: Maus, Marcela V, et al.
Publicado: (2017)

Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future
por: Betof Warner, Allison, et al.
Publicado: (2023)

Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors
por: Kobayashi, Tomoko, et al.
Publicado: (2021)

Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines
por: Srinivasan, Roopa, et al.
Publicado: (2004)

Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
por: Zamarin, Dmitriy, et al.
Publicado: (2014)

Immunotherapy and the belly of the beast
por: Merghoub, Taha, et al.
Publicado: (2014)

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
por: Ku, Geoffrey Y, et al.
Publicado: (2010)

Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8(+) T cells in the tumor microenvironment
por: Tada, Yasuko, et al.
Publicado: (2018)

Direct comparisons of T cell costimulation and checkpoint blockade in the setting of tumor-targeted monoclonal antibody therapy
por: Khalil, Danny, et al.
Publicado: (2015)

Shared cancer neoantigens: Making private matters public
por: Klebanoff, Christopher A., et al.
Publicado: (2018)

The many faces of the anti-COVID immune response
por: Vardhana, Santosha A., et al.
Publicado: (2020)

Model-based clustering for flow and mass cytometry data with clinical information
por: Abe, Ko, et al.
Publicado: (2020)

Model-based cell clustering and population tracking for time-series flow cytometry data
por: Minoura, Kodai, et al.
Publicado: (2019)

CYBERTRACK2.0: zero-inflated model-based cell clustering and population tracking method for longitudinal mass cytometry data
por: Minoura, Kodai, et al.
Publicado: (2020)

Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma
por: Loo, Kimberly, et al.
Publicado: (2022)

Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma
por: Yuan, Jianda, et al.
Publicado: (2013)

Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy
por: Lesokhin, Alexander M., et al.
Publicado: (2013)

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B., et al.
Publicado: (2013)

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B, et al.
Publicado: (2013)

Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors
por: Zamarin, Dmitriy, et al.
Publicado: (2014)

Imaging findings of granulocyte colony-stimulating factor-producing tumors: a case series and review of the literature
por: Kohno, Shigeshi, et al.
Publicado: (2021)

Non-contrast-enhanced MR portography and hepatic venography with time-spatial labeling inversion pulses: comparison at 1.5 Tesla and 3 Tesla
por: Ohno, Tsuyoshi, et al.
Publicado: (2015)

Hiding the road signs that lead to tumor immunity
por: Schaer, David A., et al.
Publicado: (2011)

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
por: Schaer, David A, et al.
Publicado: (2014)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

How Changes in Affinity of Corticosteroid-binding Globulin Modulate Free Cortisol Concentration
por: Chan, Wee Lee, et al.
Publicado: (2013)

Depletion of central memory CD8(+) T cells might impede the antitumor therapeutic effect of Mogamulizumab
por: Maeda, Yuka, et al.
Publicado: (2021)

Self-antigen–specific CD8(+) T cell precursor frequency determines the quality of the antitumor immune response
por: Rizzuto, Gabrielle A., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_jd0lda2k1ve1ckokh89kko4v34